The Following IRB Review Fees Are in Effect Beginning November 1, 2016:
Continuing review: $1000
- the study is funded by the federal government; or by a university or another non-profit entity; or
- the study is investigator-initiated; or
- the study uses an external IRB as its IRB-of-record, and the DUHS IRB performs an administrative review; or
- the activity qualifies for expedited review or is declared exempt from further IRB review by an IRB Chair/designee.
There will be no charge for Single Patient Treatment Use Requests.
The fees for protocols received by the IRB before November 1, 2016 remain under the previous fee schedule for the duration of the study.
Any requests for exception should be submitted by the CRU Medical Director to Dr. Adrian Hernandez, MD, Vice Dean for Clinical Research.